#In Vitro Diagnostic (IVD) market forecast
Explore tagged Tumblr posts
Text
In Vitro Diagnostics (IVD) Industry Sales, Demand, Regional Outlook And Supply Chain Analysis till 2030
The global in vitro diagnostics (IVD) market reached an estimated size of USD 77.92 billion in 2023, with expectations for a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This market growth is primarily driven by the increasing use of IVD tools due to rising cases of infectious and chronic diseases worldwide. Automated IVD systems are becoming more common in hospitals and laboratories, as they provide accurate, fast, and error-free diagnoses, helping meet the growing demand for efficient healthcare services. Additionally, IVD market expansion is fueled by frequent product launches from key industry players. For example, in November 2023, ARUP Laboratories received a CE mark from the EU-IVDR for AAV5 DetectCDx, a companion diagnostic that helps identify eligibility for severe hemophilia Some patients to receive BioMarin’s gene therapy, Roctavian.
Major companies in the IVD market are employing various strategies to strengthen their position and bring more advanced and diverse products to their customers. New product launches and partnerships are among the most common tactics. For instance, in March 2023, BD received FDA 510(k) clearance for the BD Vaginal Panel on its BD COR System, a tool designed to detect infectious causes of vaginitis. In another instance, in August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These partnerships and product developments highlight how key players are focused on expanding their diagnostic offerings to meet growing healthcare needs.
Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market
Supportive initiatives from government and non-governmental bodies are also contributing to the market's growth by enhancing access to essential diagnostic tools. In October 2023, the World Health Organization (WHO) released an updated Essential Diagnostics List (EDL), a comprehensive catalog of vital IVD products that aids countries in making informed decisions on diagnostic tools. This list provides evidence-based recommendations, ensuring that essential diagnostic products are accessible to the people who need them most. Additionally, in August 2023, the Africa CDC collaborated with the Africa Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) to improve access to diagnostic tests across the African continent. Such initiatives are expected to further support the expansion of the IVD market, especially in regions with limited healthcare resources.
The global aging population, coupled with growing awareness of early disease detection, has led to an increase in routine check-ups. This trend is particularly relevant because the majority of deaths due to infections and chronic conditions occur in people over 75. According to the UK's Office for Budget Responsibility, healthcare costs have seen a significant rise, which can place economic strain on countries with rapidly aging populations. However, these increased expenditures are likely to boost the IVD market, as diagnostic testing becomes essential in managing the healthcare needs of older adults.
End-use Segmentation Insights:
Hospitals represented the largest revenue share in the IVD market in 2023, largely due to an increase in hospital admissions requiring rapid diagnostic support. The continuous development of healthcare infrastructure, supported by government initiatives, is further improving hospital facilities, thereby increasing demand for hospital-based IVD testing. IVD tests are frequently purchased by hospitals and are utilized in large volumes due to their critical role in providing fast, accurate results for patient care. In the U.S. alone, there are over 6,129 hospitals, all of which rely on IVD tests for essential decision-making in patient care.
In December 2023, the American Hospital Association advocated to the FDA that regulatory requirements for devices should not apply to hospitals' laboratory-developed tests (LDTs), which could allow hospitals greater flexibility in their use of in-house diagnostic tools. Meanwhile, the homecare segment is anticipated to see high growth from 2024 to 2030, driven by the aging population and increasing demand for at-home diagnostic devices. There is a particular need for novel molecular diagnostic and immunoassay platforms that enable patients to perform self-tests conveniently at home. For example, in February 2023, the FDA granted Emergency Use Authorization (EUA) to the first over-the-counter (OTC) home diagnostic test capable of distinguishing between influenza A, influenza B, and SARS-CoV-2 (the virus causing COVID-19). This authorization demonstrates the shift towards providing individuals with more autonomy in managing their health through accessible at-home testing solutions.
Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.
#In Vitro Diagnostics (IVD) Industry#In Vitro Diagnostics (IVD) Market Research#In Vitro Diagnostics (IVD) Market Forecast
0 notes
Text
In Vitro Diagnostics (IVD) Industry Growth Analysis & Forecast Research Report, 2030
The global in vitro diagnostics (IVD) market reached an estimated size of USD 77.92 billion in 2023, with expectations for a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This market growth is primarily driven by the increasing use of IVD tools due to rising cases of infectious and chronic diseases worldwide. Automated IVD systems are becoming more common in hospitals and laboratories, as they provide accurate, fast, and error-free diagnoses, helping meet the growing demand for efficient healthcare services. Additionally, IVD market expansion is fueled by frequent product launches from key industry players. For example, in November 2023, ARUP Laboratories received a CE mark from the EU-IVDR for AAV5 DetectCDx, a companion diagnostic that helps identify eligibility for severe hemophilia Some patients to receive BioMarin’s gene therapy, Roctavian.
Major companies in the IVD market are employing various strategies to strengthen their position and bring more advanced and diverse products to their customers. New product launches and partnerships are among the most common tactics. For instance, in March 2023, BD received FDA 510(k) clearance for the BD Vaginal Panel on its BD COR System, a tool designed to detect infectious causes of vaginitis. In another instance, in August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These partnerships and product developments highlight how key players are focused on expanding their diagnostic offerings to meet growing healthcare needs.
Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market
Supportive initiatives from government and non-governmental bodies are also contributing to the market's growth by enhancing access to essential diagnostic tools. In October 2023, the World Health Organization (WHO) released an updated Essential Diagnostics List (EDL), a comprehensive catalog of vital IVD products that aids countries in making informed decisions on diagnostic tools. This list provides evidence-based recommendations, ensuring that essential diagnostic products are accessible to the people who need them most. Additionally, in August 2023, the Africa CDC collaborated with the Africa Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) to improve access to diagnostic tests across the African continent. Such initiatives are expected to further support the expansion of the IVD market, especially in regions with limited healthcare resources.
The global aging population, coupled with growing awareness of early disease detection, has led to an increase in routine check-ups. This trend is particularly relevant because the majority of deaths due to infections and chronic conditions occur in people over 75. According to the UK's Office for Budget Responsibility, healthcare costs have seen a significant rise, which can place economic strain on countries with rapidly aging populations. However, these increased expenditures are likely to boost the IVD market, as diagnostic testing becomes essential in managing the healthcare needs of older adults.
End-use Segmentation Insights:
Hospitals represented the largest revenue share in the IVD market in 2023, largely due to an increase in hospital admissions requiring rapid diagnostic support. The continuous development of healthcare infrastructure, supported by government initiatives, is further improving hospital facilities, thereby increasing demand for hospital-based IVD testing. IVD tests are frequently purchased by hospitals and are utilized in large volumes due to their critical role in providing fast, accurate results for patient care. In the U.S. alone, there are over 6,129 hospitals, all of which rely on IVD tests for essential decision-making in patient care.
In December 2023, the American Hospital Association advocated to the FDA that regulatory requirements for devices should not apply to hospitals' laboratory-developed tests (LDTs), which could allow hospitals greater flexibility in their use of in-house diagnostic tools. Meanwhile, the homecare segment is anticipated to see high growth from 2024 to 2030, driven by the aging population and increasing demand for at-home diagnostic devices. There is a particular need for novel molecular diagnostic and immunoassay platforms that enable patients to perform self-tests conveniently at home. For example, in February 2023, the FDA granted Emergency Use Authorization (EUA) to the first over-the-counter (OTC) home diagnostic test capable of distinguishing between influenza A, influenza B, and SARS-CoV-2 (the virus causing COVID-19). This authorization demonstrates the shift towards providing individuals with more autonomy in managing their health through accessible at-home testing solutions.
Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.
#In Vitro Diagnostics (IVD) Industry#In Vitro Diagnostics (IVD) Market Research#In Vitro Diagnostics (IVD) Market Forecast
0 notes
Text
In Vitro Diagnostics (IVD) Industry In-depth Analysis and Forecast Report, 2030
The global in vitro diagnostics (IVD) market reached an estimated size of USD 77.92 billion in 2023, with expectations for a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This market growth is primarily driven by the increasing use of IVD tools due to rising cases of infectious and chronic diseases worldwide. Automated IVD systems are becoming more common in hospitals and…
0 notes
Text
Exploring the Growth of the In Vitro Diagnostic (IVD) Market: Key Trends and Insights
The In Vitro Diagnostic (IVD) market is projected to be valued at USD 95.59 billion in 2024, with expectations to grow to USD 125.61 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.62% during the forecast period from 2024 to 2029
The In Vitro Diagnostic (IVD) market has been experiencing robust growth, fueled by advancements in medical technology, an aging population, and increasing demand for early diagnosis and precision medicine. IVD refers to tests conducted on biological samples such as blood, urine, and tissues to diagnose diseases, monitor health conditions, or predict treatment outcomes. These diagnostic tests are critical in guiding clinical decisions and improving patient care.
Key Drivers of the IVD Market
Technological Advancements Cutting-edge technologies like molecular diagnostics, next-generation sequencing (NGS), and point-of-care (POC) testing are revolutionizing the IVD market. Molecular diagnostics, in particular, allow for the detection of specific genetic markers, enabling early detection of diseases such as cancer and genetic disorders. NGS is enhancing personalized medicine by identifying precise mutations in a patient’s DNA, making treatments more targeted and effective.
Aging Population and Chronic Diseases The global aging population is contributing to the rise in chronic diseases such as diabetes, cardiovascular conditions, and cancer. As these conditions require continuous monitoring and management, the demand for IVD tests has increased. For instance, diabetes patients rely on glucose monitoring systems, which are a significant segment of the IVD market. This trend is expected to drive further growth in the coming years.
Rising Demand for Point-of-Care Testing POC testing, which allows for rapid diagnostic results at the patient’s bedside or in non-laboratory settings, is becoming increasingly popular. This technology enables quicker decision-making, especially in emergency situations, and reduces the need for centralized lab facilities. With advancements in POC technology, tests for conditions like COVID-19, diabetes, and infectious diseases are becoming more accessible and efficient.
Personalized Medicine and Companion Diagnostics The shift towards personalized medicine is one of the most significant trends in healthcare today. Companion diagnostics, a segment of IVD, plays a crucial role in determining the suitability of specific therapies based on a patient’s genetic makeup. This approach not only enhances treatment effectiveness but also minimizes adverse drug reactions, improving patient outcomes.
COVID-19 Impact The pandemic significantly boosted the IVD market, particularly in the areas of molecular diagnostics and POC testing. The urgent need for COVID-19 testing drove innovations in rapid testing kits, which have now become a critical part of pandemic management. As healthcare systems around the world continue to prioritize pandemic preparedness, this surge in demand for infectious disease testing is expected to persist.
Challenges Facing the IVD Industry
Despite the positive growth trajectory, the IVD market faces several challenges:
Regulatory Hurdles: IVD products must undergo stringent regulatory approvals before being brought to market, which can delay commercialization. Different regions have varying regulatory requirements, adding complexity for companies operating globally.
Reimbursement Issues: Securing reimbursement for IVD tests, especially in the case of novel diagnostics, can be a barrier to widespread adoption. In many markets, healthcare systems may be slow to integrate these tests into routine care due to cost concerns.
Data Privacy Concerns: As more IVD tests incorporate digital platforms and patient data, concerns over data security and privacy have risen. Ensuring that patient information is protected is critical to maintaining trust in IVD technologies.
Regional Insights
North America: The largest market for IVD, driven by well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and favorable government policies supporting innovation.
Europe: Strong growth is anticipated, particularly in molecular diagnostics and cancer testing. Countries such as Germany, France, and the UK are leading in research and development within the field.
Asia-Pacific: The fastest-growing region due to the rising prevalence of chronic diseases, increasing healthcare expenditure, and improving healthcare infrastructure in countries like China and India.
Future Outlook
The future of the IVD market looks promising, with continued advancements in technology and an increasing focus on precision medicine. The integration of artificial intelligence (AI) and machine learning into diagnostic tools is expected to improve the accuracy of tests and allow for the analysis of large datasets in real-time. Additionally, the ongoing emphasis on personalized healthcare will drive demand for companion diagnostics and genetic testing.
With the global healthcare landscape rapidly evolving, the In Vitro Diagnostic market is well-positioned for sustained growth. Companies investing in innovation, regulatory compliance, and expanding access to diagnostics in emerging markets will be the key players shaping the future of this dynamic industry.
Conclusion
The In Vitro Diagnostic market is a vital part of modern healthcare, providing the tools needed for accurate and timely diagnosis of diseases. As new technologies emerge and patient demand for personalized care grows, the IVD industry is set to expand further, offering innovative solutions that enhance healthcare outcomes and improve the quality of life for patients worldwide.
#In Vitro Diagnostic (IVD) market trends#In Vitro Diagnostic (IVD) market size#In Vitro Diagnostic (IVD) market share#In Vitro Diagnostic (IVD) market analysis#In Vitro Diagnostic (IVD) market forecast#In Vitro Diagnostic (IVD) market demand
0 notes
Text
#In Vitro Diagnostics (IVD) Market Size in 2022 : Share#Trends#Opportunities Analysis Forecast Report By 2028 | 181 Pages Report#intellectualmarketinsights
0 notes
Text
The Business Research Company offers in vitro diagnostics ivd quality control market research report 2023 with industry size, share, segments and market growth
#in vitro diagnostics quality control market#ivd market share#ivd market growth#ivd market forecast#ivd market trends#ivd market size#ivd market analysis#global ivd market#ivd industry#ivd market report#ivd market research#ivd market outlook
0 notes
Text
Global In Vitro Diagnostics (IVD) Market Report 2022| Research Analysis with Trends, Segmentation, Share and Forecast by 2030| By R&I
The report is titled as ‘In Vitro Diagnostics Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the In Vitro Diagnostics market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. In Vitro Diagnostics market is expected to grow with significant rate in the near future.
The global In Vitro Diagnostics (IVD) market in 2020 is estimated for more than US$ 70,561.9 Mn and expected to reach a value of US$ 1,03,310.9 Mn by 2028 with a significant CAGR of 4.9%.
Request a Sample Copy of this Report @: https://reportsandinsights.com/sample-request/1256
In Vitro Diagnostics Market Dynamics
In-vitro diagnostics are tests performed in laboratories on biological samples such as blood, urine, tissue, etc. In vitro diagnostic are not only used for diagnosis but also provides useful information on monitoring of disease and treatment. Two-thirds of today’s clinical diagnoses involve in vitro diagnostics, hence are referred to as the backbone of healthcare.
In-vitro diagnostics market has witnessed substantial growth in last decade owing to technological advancements in testing methods as well as in analyzer instruments. According to the EPRS report, there are over 40,000 different IVD products available in the European market and per capita annual spending on IVD is approximately US$ 26. In-vitro diagnostics help to reduce the healthcare cost by making treatments more efficient and precise.
Evolving regulations for in-vitro diagnostics is the major driving force for market growth over the forecast period. For instance, regulation of medical devices in the European Union (EU) is undergoing a significant transformation with expanding the scope for in vitro diagnostics, which is expected to impact the increased product approvals for IVD in the region. Significant progress in point-of-care testing is another factor driving the growth of the global in-vitro diagnostics market. Introduction of molecular based assays and identification of range of biomarkers has opened up huge new opportunity for growth of global in-vitro diagnostics market.
MMC Overview on In Vitro Diagnostics Market Report
The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.
A research report on the In Vitro Diagnostics market by Reports and Insights is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.
Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.
Wish to Know More About the Study? Click here to get a Report Description: https://reportsandinsights.com/pressrelease/global-in-vitro-diagnostics-market
In Vitro Diagnostics Market Segmentation
The global in vitro diagnostics market is segmented on the basis of product type, technology, end user and region. On the basis of product type, in vitro diagnostics market is segmented as reagents and kits, analyze, and consumables. Based on technology, global market is segmented as immunochemistry, molecular diagnostics, hematology, point-of-care diagnostics, tissue diagnostics and clinical chemistry. On the basis of end user, global in vitro diagnostics market is segmented into hospitals, diagnostic centers, clinics, home care settings and others.
By Products & Services
Reagents & Kits
Instruments
Fully Automated Instruments
Semi-Automated Instruments
Other Instruments
Data Management Software
Services
By Technology
mmunoassay/Immunochemistry
Enzyme-Linked Immunosorbent Assay
hemiluminescence Immunoassays
Fluorescence Immunoassays
Colorimetric Immunoassays
Radioimmunoassay
Rapid Test
Western Blotting
Enzyme-Linked Immunospot Assays
Clinical Chemistry
Basic Metabolic Panel
Electrolyte Panel
Liver Panel
Lipid Profile
Renal Profile
Thyroid Function Panel
Specialty Chemical Tests
Molecular Diagnostics
Polymerase Chain Reaction
Isothermal Nucleic Acid Amplification Technology
Microarray
Hybridization
DNA Sequencing & Next-Generation Sequencing
Other Mdx Technologies
Microbiology
Hematology
Coagulation and Hemostasis
Urinalysis
Other IVD Technologies
By Application
Infectious Diseases
Diabetes
Oncology
Cardiology
Autoimmune Diseases
Nephrology
Drug Testing/Pharmacogenomics
HIV/Aids
Other Applications
By End User
Hospitals
Laboratories
Large/Reference Laboratories
Medium-Sized Laboratories
Small Laboratories
Point-Of-Care Testing
Patient Self-Testing
Academic Institutes
Other End Users
By Region
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
In Vitro Diagnostics Market Competitive Landscape
Global market for in vitro diagnostics is dominated by Abbott Laboratories, Merck KGaG, F. Hoffman-La Roche AG, Becton Dickinson & Company, Danaher Corporation, Thermo Fisher Scientific Inc., Qiagen N.V., Diasorin S.P.A., biomerieux SA, Alere Inc., Bayer AG, Bio-Rad Laboratories Inc., Sysmex Corporation, etc. to name a few.
To view Top Players, Segmentation and other Statistics of In Vitro Diagnostics (IVD) Industry, Get Sample Report @: https://reportsandinsights.com/sample-request/1256
About Reports and Insights:
Reports and Insights is one of the leading market research companies which offers syndicate and consulting research around the globe. At Reports and Insights, we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
Contact Us:
Neil Jonathan
1820 Avenue M, Brooklyn
NY 11230, United States
+1-(718) 312-8686
Find Us on LinkedIn: www.linkedin.com/company/report-and-insights/
View Latest Market Updates At: https://marketsresearchanalytics.com
#In Vitro Diagnostics (IVD) Market Research#In Vitro Diagnostics (IVD) Market Report#In Vitro Diagnostics (IVD) Market Share 2021#In Vitro Diagnostics (IVD) Market Size 2022#In Vitro Diagnostics (IVD) Market Trends#In Vitro Diagnostics (IVD) Market Key Players#Global In Vitro Diagnostics (IVD) Market Analysis#In Vitro Diagnostics (IVD) Industry News#In Vitro Diagnostics (IVD) Industry Analysis#In Vitro Diagnostics (IVD) Market Forecast#In Vitro Diagnostics (IVD) Market CAGR#USA In Vitro Diagnostics (IVD) Market#Japan In Vitro Diagnostics (IVD) Market#In Vitro Diagnostics (IVD) Market Demand#Argentina In Vitro Diagnostics (IVD) Market#Australia In Vitro Diagnostics (IVD) Market#Belgium In Vitro Diagnostics (IVD) Market#Brazil In Vitro Diagnostics (IVD) Market#Canada In Vitro Diagnostics (IVD) Market#Chile In Vitro Diagnostics (IVD) Market#China In Vitro Diagnostics (IVD) Market#Columbia In Vitro Diagnostics (IVD) Market#Egypt In Vitro Diagnostics (IVD) Market#France In Vitro Diagnostics (IVD) Market#Germany In Vitro Diagnostics (IVD) Market#Global In Vitro Diagnostics (IVD) Market#India In Vitro Diagnostics (IVD) Market#Indonesia In Vitro Diagnostics (IVD) Market#In Vitro Diagnostics (IVD) Applications#In Vitro Diagnostics (IVD) Industry
0 notes
Text
In Vitro Diagnostics (IVD) Quality Control Market Analysis, Demand & Forecast to 2020 – Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK)
Market Overview
The global in vitro diagnostics quality control market was valued at USD 1.5 billion in 2021 and it is anticipated to grow further up to USD 2.2 billion by 2031, at a CAGR of 3.7% during the forecast period.
The effectiveness of in vitro diagnostic tests, including those for pathogen identification using in vitro nucleic acid testing, healthcare-associated illnesses (HAIs) such as pneumonia, urinary tract infections, and others, is assessed using IVD quality controls. These products primarily concentrate on defect detection, quality control, and validation panels like the Blood Culture (BCID) Control Panel, Human Papillomavirus (HPV) Control Panel, and others to support in the implementation and monitoring of the performance of clinical and research laboratories, blood diagnostic centers, and IVD manufacturers.
View Detailed Report Description: https://www.globalinsightservices.com/reports/in-vitro-diagnostics-ivd-quality-control-market/
Market Dynamics
As the burden of various diseases increases globally, so has the number of laboratory tests. The number of laboratories in both the public and private sectors has increased in response to this need. With the start of the COVID-19 pandemic in December 2019, the demand for diagnostic tests has skyrocketed. Many government organizations have established new laboratories in response to this epidemic and to increase laboratory testing capacity. The majority of nations need clinical laboratories to get regulatory body accreditation before performing diagnostic tests. Additionally, accreditation to ISO 15189:2012 and other comparable standards is turning into a requirement in many nations. Authorities assess a laboratory’s competency and quality system during the accreditation process using predetermined standards. While some European nations, including Belgium, France, Hungary, Ireland, and Lithuania, require accreditation for a variety of laboratory tests, others, like Finland, the Netherlands, Sweden, Switzerland, and the UK, have practically finished the process.
It costs a lot of money to set up a QC process in a clinical laboratory. Additionally, laboratories must keep a specialized staff on hand to oversee the QC system. Moreover, regardless of the number of tests conducted, QC procedures are expensive. As a result, QC methods are particularly expensive to adopt for clinical laboratories that perform few diagnostic tests. This is predicted to lead to a lesser adoption of QC procedures, along with budgetary restrictions in many hospitals and laboratories in developed and emerging nations.
Get Free Sample Copy of This Report: https://www.globalinsightservices.com/request-sample/GIS10301
The key players studied in the global in vitro diagnostic quality control market are Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific, Inc. (US), LGC Limited (UK), Abbott Laboratories (US), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Fortress Diagnostics (UK), SERO AS (US), Sysmex Corporation (Japan), Ortho-Clinical Diagnostics (US), and Helena Laboratories Corporation (US) among others.
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1–833–761–1700
2 notes
·
View notes
Text
The Future of Health: Navigating the Growing In Vitro Diagnostics Market
Market Size Overview
The In Vitro Diagnostics Market is projected to be valued at approximately USD 95.59 billion in 2024, with expectations to reach around USD 125.61 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.62% during the forecast period from 2024 to 2029.
Market Overview
The In Vitro Diagnostics (IVD) industry is experiencing significant growth driven by advancements in technology, an increasing prevalence of chronic diseases, and a rising demand for personalized medicine. As healthcare systems evolve, the emphasis on early disease detection and monitoring further propels the market forward.
Key Trends
Technological Advancements: Innovations in molecular diagnostics, point-of-care testing, and automation are enhancing the accuracy and efficiency of diagnostic procedures.
Rising Demand for Home Testing: The trend toward at-home diagnostic kits is on the rise, fueled by consumer preference for convenience and privacy, especially post-pandemic.
Personalized Medicine: Increasing adoption of targeted therapies necessitates precise diagnostic tools, driving demand for specific IVD tests tailored to individual patient needs.
Regulatory Changes: Evolving regulatory frameworks are influencing market dynamics, as companies adapt to new compliance requirements to ensure product safety and efficacy.
Global Health Initiatives: Government investments in healthcare infrastructure and disease prevention programs are enhancing access to diagnostic services, particularly in emerging markets.
Challenges
Despite its promising growth, the IVD market faces challenges such as stringent regulatory requirements, high costs of advanced diagnostic technologies, and the need for continuous innovation to keep pace with rapid scientific advancements. Additionally, competition from established players and emerging startups can impact market entry for new companies.
Conclusion
The In Vitro Diagnostics industry is poised for robust growth, driven by technological advancements and a heightened focus on early disease detection. While challenges exist, the overall outlook remains positive, suggesting that stakeholders should remain agile and innovative to capitalize on emerging opportunities in this dynamic market.
#In Vitro Diagnostics industry#In Vitro Diagnostics market#In Vitro Diagnostics market size#In Vitro Diagnostics market share#In Vitro Diagnostics market trends#In Vitro Diagnostics market analysis#In Vitro Diagnostics market growth#In Vitro Diagnostics industry overview
0 notes
Text
In Vitro Diagnostics (IVD) Industry Size, Trends, Value, Sales and Forecast 2030
The global in vitro diagnostics (IVD) market was valued at approximately USD 77.92 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This growth can be attributed to several factors, including the increasing adoption of IVD technologies due to the rising prevalence of infectious and chronic diseases. The development and integration of automated IVD systems in laboratories and hospitals, which aim to deliver more efficient, accurate, and error-free diagnoses, are also expected to significantly drive market growth. Additionally, the continuous introduction of new IVD products by key industry players contributes to this positive trend. For instance, in November 2023, ARUP Laboratories obtained a CE mark under the EU-IVDR for the AAV5 DetectCDx, a companion diagnostic test that determines the eligibility of patients with severe hemophilia A for BioMarin's gene therapy, Roctavian.
Technological advancements in IVD systems, particularly improvements in accuracy, portability, and cost-effectiveness, are among the high-impact factors influencing this market. Innovations in highly accurate clinical laboratory tests are fostering global adoption of novel IVD diagnostics. For example, in June 2023, Japan's Ministry of Health, Labour, and Welfare granted marketing approval to Toray Industries, Inc. for its Toray APOA2-iTQ, a diagnostic tool used for pancreatic cancer detection. Similarly, in March 2023, Abbott received U.S. FDA clearance for its novel laboratory blood test for Traumatic Brain Injury (TBI). These developments highlight the increasing approval of IVD tests targeting life-threatening diseases, which is expected to create significant opportunities in untapped market segments.
Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market
Leading companies in the IVD market are adopting diverse strategies to strengthen their positions, often introducing new products and forming partnerships to attract more customers and meet evolving diagnostic needs. For instance, in March 2023, BD received 510(k) clearance from the U.S. FDA for its BD Vaginal Panel on the BD COR System, aimed at detecting infectious causes of vaginitis. In August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These strategic collaborations and product launches are critical for companies seeking to leverage cutting-edge technologies in diagnostics.
Product Segmentation Insights:
In terms of products, the reagents segment accounted for the largest market share, representing 65.88% of total revenue in 2023. This segment is expected to maintain its dominance, growing at the fastest CAGR from 2024 to 2030. The growth of the reagents segment is driven by extensive research and development (R&D) efforts by key players aimed at developing novel reagents and test kits. For example, in February 2023, BD received market approval for its BD Onclarity HPV Assay, which is used with the ThinPrep Pap Test in the U.S. Ongoing R&D efforts focused on faster cancer detection and precision medicine are prompting companies to concentrate on specialized, profitable areas of the IVD market. In March 2023, QIAGEN formed a partnership with Servier to develop a companion diagnostic test for TIBSOVO, which is indicated for the treatment of acute myeloid leukemia, a type of blood cancer.
The growing demand for precision medicine is expected to further boost the overall demand for these novel reagents and consumables. The instruments segment held the second-largest share of the IVD market in 2023. Increasing approvals of novel IVD instruments are likely to contribute to the segment's growth. For instance, in April 2023, bioMérieux SA submitted a 510(k) application to the U.S. FDA for VITEK REVEAL, a rapid antimicrobial susceptibility testing (AST) system. Moreover, companies are aligning their instrument launches to meet the increasing demand for genetic tests globally. In March 2022, Thermo Fisher Scientific introduced the Ion Torrent Genexus Dx Integrated Sequencer for both research and diagnostic purposes, showcasing the alignment of technological advancements with the growing needs of genetic testing.
In conclusion, the global IVD market is poised for substantial growth, driven by the increasing incidence of infectious and chronic diseases, rising demand for precision medicine, and ongoing advancements in diagnostic technologies. Companies are continuously innovating, launching new products, and forming strategic partnerships to meet the evolving needs of healthcare providers and patients, which will further accelerate market expansion.
Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.
#In Vitro Diagnostics (IVD) Industry#In Vitro Diagnostics (IVD) Market Share#In Vitro Diagnostics (IVD) Market Trends#In Vitro Diagnostics (IVD) Market Growth
0 notes
Text
In Vitro Diagnostics (IVD) Market Growth Analysis & Forecast Research Report, 2030
The global in vitro diagnostics (IVD) market was valued at approximately USD 77.92 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This growth can be attributed to several factors, including the increasing adoption of IVD technologies due to the rising prevalence of infectious and chronic diseases. The development and integration of automated IVD systems in laboratories and hospitals, which aim to deliver more efficient, accurate, and error-free diagnoses, are also expected to significantly drive market growth. Additionally, the continuous introduction of new IVD products by key industry players contributes to this positive trend. For instance, in November 2023, ARUP Laboratories obtained a CE mark under the EU-IVDR for the AAV5 DetectCDx, a companion diagnostic test that determines the eligibility of patients with severe hemophilia A for BioMarin's gene therapy, Roctavian.
Technological advancements in IVD systems, particularly improvements in accuracy, portability, and cost-effectiveness, are among the high-impact factors influencing this market. Innovations in highly accurate clinical laboratory tests are fostering global adoption of novel IVD diagnostics. For example, in June 2023, Japan's Ministry of Health, Labour, and Welfare granted marketing approval to Toray Industries, Inc. for its Toray APOA2-iTQ, a diagnostic tool used for pancreatic cancer detection. Similarly, in March 2023, Abbott received U.S. FDA clearance for its novel laboratory blood test for Traumatic Brain Injury (TBI). These developments highlight the increasing approval of IVD tests targeting life-threatening diseases, which is expected to create significant opportunities in untapped market segments.
Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market
Leading companies in the IVD market are adopting diverse strategies to strengthen their positions, often introducing new products and forming partnerships to attract more customers and meet evolving diagnostic needs. For instance, in March 2023, BD received 510(k) clearance from the U.S. FDA for its BD Vaginal Panel on the BD COR System, aimed at detecting infectious causes of vaginitis. In August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These strategic collaborations and product launches are critical for companies seeking to leverage cutting-edge technologies in diagnostics.
Product Segmentation Insights:
In terms of products, the reagents segment accounted for the largest market share, representing 65.88% of total revenue in 2023. This segment is expected to maintain its dominance, growing at the fastest CAGR from 2024 to 2030. The growth of the reagents segment is driven by extensive research and development (R&D) efforts by key players aimed at developing novel reagents and test kits. For example, in February 2023, BD received market approval for its BD Onclarity HPV Assay, which is used with the ThinPrep Pap Test in the U.S. Ongoing R&D efforts focused on faster cancer detection and precision medicine are prompting companies to concentrate on specialized, profitable areas of the IVD market. In March 2023, QIAGEN formed a partnership with Servier to develop a companion diagnostic test for TIBSOVO, which is indicated for the treatment of acute myeloid leukemia, a type of blood cancer.
The growing demand for precision medicine is expected to further boost the overall demand for these novel reagents and consumables. The instruments segment held the second-largest share of the IVD market in 2023. Increasing approvals of novel IVD instruments are likely to contribute to the segment's growth. For instance, in April 2023, bioMérieux SA submitted a 510(k) application to the U.S. FDA for VITEK REVEAL, a rapid antimicrobial susceptibility testing (AST) system. Moreover, companies are aligning their instrument launches to meet the increasing demand for genetic tests globally. In March 2022, Thermo Fisher Scientific introduced the Ion Torrent Genexus Dx Integrated Sequencer for both research and diagnostic purposes, showcasing the alignment of technological advancements with the growing needs of genetic testing.
In conclusion, the global IVD market is poised for substantial growth, driven by the increasing incidence of infectious and chronic diseases, rising demand for precision medicine, and ongoing advancements in diagnostic technologies. Companies are continuously innovating, launching new products, and forming strategic partnerships to meet the evolving needs of healthcare providers and patients, which will further accelerate market expansion.
Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.
#In Vitro Diagnostics (IVD) Industry#In Vitro Diagnostics (IVD) Market Share#In Vitro Diagnostics (IVD) Market Trends#In Vitro Diagnostics (IVD) Market Growth
0 notes
Text
Meticulous Research® Forecasts Middle East IVD Market to Reach $2.15 Billion by 2031
The report highlights market dynamics, growth drivers, key challenges, and opportunities across the region.
Meticulous Research®, a globally recognized leader in market intelligence, has released a new report titled, "Middle East IVD Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab) - Forecast to 2031." According to the findings, the Middle East in vitro diagnostics (IVD) market is projected to reach $2.15 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031.
Key Market Drivers
The growth of the Middle East IVD market is driven by several factors, including the rising prevalence of chronic and infectious diseases, increased demand for point-of-care (PoC) and rapid diagnostic solutions, expanding healthcare expenditures, and an aging population. Moreover, growing healthcare awareness, especially in countries such as the UAE and Saudi Arabia, is also contributing to market expansion. However, the high costs associated with IVD tests and inconsistencies in results from rapid diagnostic tests present challenges to sustained growth.
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5764
Emerging Opportunities
Increasing awareness around early disease detection and personalized medicine, particularly in the UAE and Saudi Arabia, is creating opportunities for market players. These regions are witnessing an uptick in the adoption of advanced diagnostic technologies, which is expected to fuel demand in the coming years. Nonetheless, issues such as false positives in immunoassays and PoC tests remain significant hurdles that stakeholders need to address.
Competitive Landscape
The Middle East IVD market is dominated by global healthcare giants such as Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), and Siemens Healthineers AG (Germany). Other key players include QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (U.S.), and Bio-Rad Laboratories, Inc. (U.S.), among others.
Request Sample Report Here: https://www.meticulousresearch.com/request-sample-report/cp_id=5764
Market Segmentation Insights
The report provides a detailed breakdown of the Middle East IVD market based on various parameters:
Offerings: The kits and reagents segment is expected to register the highest growth rate due to their extensive use in diagnosing chronic and infectious diseases. This is attributed to the increasing volume of tests for diseases such as HIV and influenza, alongside growing consumer awareness of self-testing options.
Technologies: Molecular diagnostics, including PCR and next-generation sequencing (NGS), is expected to capture the largest market share in 2024, driven by the rising prevalence of communicable and non-communicable diseases and the need for high-volume, accurate testing.
Applications: Infectious disease testing is set to dominate the market, with respiratory infections, hepatitis, HIV, and sexually transmitted diseases (STDs) being the primary drivers. The region's aging population and increasing healthcare demand are also contributing to the rise in testing.
Diagnostic Approach: Point-of-care testing is expected to exhibit the highest growth, propelled by the increasing burden of chronic diseases and the launch of innovative PoC diagnostics by market leaders.
End Users: Hospitals and clinics will continue to be the largest segment, performing a wide range of diagnostic tests for various medical conditions, particularly in urban areas where access to healthcare services is more robust.
Access Full Report Details Here : https://www.meticulousresearch.com/request-sample-report/cp_id=5764
Country Insights
Among the Middle Eastern countries, Saudi Arabia is projected to dominate the IVD market in 2024, largely due to its rapidly aging population, the high incidence of chronic and infectious diseases, and the growing adoption of self-testing. The Kingdom’s healthcare sector is also experiencing a boost thanks to its Vision 2030 strategy, which aims to elevate healthcare standards and increase investments in medical technologies. Healthcare expenditure in Saudi Arabia is expected to grow annually by 3.0% from 2022 to 2025, further supporting market growth.
Conclusion
The Middle East IVD market presents lucrative opportunities for growth, driven by evolving healthcare needs, technological advancements, and rising awareness around early disease detection. However, market players must navigate challenges related to pricing and diagnostic accuracy to fully capitalize on the region’s potential.
Quick Buy: https://www.meticulousresearch.com/Checkout/69732912
About Meticulous Research®
Meticulous Research® is a globally recognized market research and consulting firm known for delivering in-depth insights across a variety of industries. We provide high-quality market intelligence and strategic guidance to clients across the globe.
Contact Information Email: [email protected] Sales Inquiry: +1-646-781-8004 Connect with us on LinkedIn: Meticulous Research® LinkedIn
0 notes
Text
In Vitro Diagnostics Market Size and Regional Outlook Analysis 2024 - 2030
The global in vitro diagnostics market size is expected to reach USD 101.58 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 4.4% over the forecast period driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.
These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.
Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics Market
Detailed Segmentation:
Market Characteristics
Market growth stage is medium, and the pace of the market growth is decelerating. Decreasing demand for COVID-19 tests is hampering the growth. The market is characterized by a high degree of innovation owing to the increasing introduction of novel molecular diagnostics and immunoassay tests for multiple disease indications. Moreover, increasing demand for patient-centric tests is encouraging market players to develop technologically advanced products.
Product Insights
The reagents segment held the largest share of 65.88% of the overall revenue in 2023. The segment is expected to retain its dominance growing at the fastest CAGR from 2024 to 2030 owing to the extensive R&D initiatives undertaken by major players to develop novel reagents and test kits. For instance, in February 2023, BD received the market approval for the BD Onclarity HPV Assay to be used with the ThinPrep Pap Test in the U.S. The increasing R&D activities to enable faster cancer detection and precision medicine are allowing companies to focus on niche profitable areas in the IVD business. For instance, in March 2023, QIAGEN partnered with Servier to develop a companion diagnostic test for TIBSOVO, indicated for treating the blood cancer acute myeloid leukemia.
Technology Insights
The immunoassay segment accounted for the largest revenue share in 2023. Increasing incidence of chronic & communicable diseases and rising need for early diagnosis are among the key factors leading to an increase in demand for immunological methods, including different types of Enzyme-Linked Immunosorbent Assays (ELISAs). Moreover, key players are focused on R&D pertaining to development of new immunological diagnostic instruments and tests for IVD applications. For instance, in October 2023, Sysmex Corporation and Fujirebio Holdings, Inc. collaborated to enhance their R&D, production, clinical development, and marketing activities in immunoassay.
End-use Insights
The hospitals segment held the largest revenue share in 2023 owing to a rise in the rate of hospitalizations that require support from faster diagnostics. Moreover, the ongoing development of healthcare infrastructure and favorable initiatives taken by government bodies are anticipated to enhance the existing hospital facilities. Thus, the demand for hospital-based IVD tests is increasing. Most IVD devices are purchased by hospitals and used in significant volumes. In 2023, there are over 6,129 hospitals in the U.S. that require constant aid from IVD for critical decision-making, as IVD tests provide faster and more accurate results.
Test Location Insights
The others (lab-based tests) segment accounted for the largest revenue share in 2023. A large number of test analyses at one time and the higher accuracy of laboratory-based tests make them more reliable compared to PoC and home tests, giving segment a competitive edge over the other two segments. Moreover, the availability of tests that allow for sample collection at home and sending it to the laboratories for testing makes testing highly convenient for patients.
Application Insights
The infectious diseases segment dominated the market in 2023. The outbreak of the COVID-19 pandemic increased the segment share significantly in recent years. Moreover, key players are introducing novel testing products to improve access to high-quality, innovative laboratory services for patients & healthcare providers. For instance, in February 2023, BD received EUA from the U.S. FDA for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV). Such initiatives by key players to strengthen their presence are expected to drive market growth.
Regional Insights
North America dominated the market and accounted for a share of 42.28% in 2023. The region is estimated to retain its leading market position throughout the forecast period. The market in this region is collectively driven by factors, such as the rising incidence of chronic diseases, presence of strong players, increasing number of novel test launches, and supportive government funding. For instance, in January 2023, BD and CerTest Biotec received EUA from the U.S. FDA for a PCR test for Mpox virus detection in the U.S. Moreover, the increasing requirement for genetic testing for personalized health care, such as that for diabetes and cancer, is expected to drive market growth in North America.
Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.
• The global hepatitis diagnostic market size was valued at USD 3.82 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030.
• The global hematology diagnostics market size was valued at USD 7.54 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030.
Key Companies & Market Share Insights
Some of the key players operating in the in vitro diagnostics market include F. Hoffmann-La Roche Ltd.; Abbott; Quest Diagnostics Inc.; and Danaher. Market players are adopting various strategies, such as new product launches, mergers & acquisitions, and partnerships, to strengthen their product portfolios and offer diverse technologically advanced & innovative products.
Key In Vitro Diagnostics (IVD) Companies:
• Abbott
• bioMérieux SA
• QuidelOrtho Corporation
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
• Qiagen
• Sysmex Corporation
• Charles River Laboratories
• Quest Diagnostics Incorporated
• Agilent Technologies, Inc.
• Danaher Corporation
• BD
• F. Hoffmann-La Roche Ltd.
In Vitro Diagnostics Market Segmentation
Grand View Research has segmented the global in vitro diagnostics (IVD) market report based on product, technology, application, end-use, test location, and region:
IVD Product Outlook (Revenue, USD Million, 2018 - 2030)
• Instruments
• Reagents
• Services
IVD Technology Outlook (Revenue, USD Million, 2018 - 2030)
• Immunoassay
o Instruments
o Reagents
o Services
• Hematology
o Instruments
o Reagents
o Services
• Clinical Chemistry
o Instruments
o Reagents
o Services
• Molecular Diagnostics
o Instruments
o Reagents
o Services
• Coagulation
o Instruments
o Reagents
o Services
• Microbiology
o Instruments
o Reagents
o Services
• Others
o Instruments
o Reagents
o Services
IVD Application Outlook (Revenue, USD Million, 2018 - 2030)
• Infectious Diseases
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune Diseases
• Drug Testing
• Others
IVD Test Location Outlook (Revenue, USD Million, 2018 - 2030)
• Point of Care
• Home-care
• Others
IVD End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Laboratory
• Home-care
• Others
IVD Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Spain
o Italy
o Russia
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o South Korea
o Australia
o Thailand
o Singapore
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait
Order a free sample PDF of the In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.
Recent Developments
• In December 2023, ARUP Laboratories and Medicover collaborated to provide diagnostic and healthcare services in Europe. ARUP Laboratories has developed AAV5 DetectCDx in collaboration with BioMarin Pharmaceutical Inc. to select therapies for severe hemophilia A patients
• In November 2023, Veracyte joined Illumina to develop molecular tests for decentralized IVD applications. Companies are focusing on the development of Prosigna breast cancer and Percepta nasal swab tests of Veracyte
• In October 2023, Promega Corporation announced its plan to develop and commercialize companion diagnostics kits with GSK Plc to identify cancer patients with MSI-H solid tumors
• In February 2023, Unilabs announced investing over USD 200 million in Siemens Healthineers' technology and acquiring more than 400 laboratory analyzers to strengthen its laboratory infrastructure
• In February 2023, F. Hoffmann-La Roche Ltd. collaborated with Janssen Biotech Inc. to develop companion diagnostics for targeted therapies. Companion diagnostic technologies include digital pathology, NGS, PCR, immunoassays, and immunohistochemistry
#In Vitro Diagnostics Market#In Vitro Diagnostics Market size#In Vitro Diagnostics Market share#In Vitro Diagnostics Market analysis#In Vitro Diagnostics Industry
0 notes
Text
United States In-Vitro Diagnostics (IVD) Market size at USD 33.50 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects United States In-Vitro Diagnostics (IVD) Market size to expand at a CAGR of 5.70% reaching a value of USD 49.10 billion by 2030. The growing elderly population and the increasing incidence of both communicable and non-communicable diseases are key drivers of United States in-vitro diagnostics (IVD) market. The number of point-of-care tests is also rising along with the use of automation in labs and automated equipment, which is expected to provide United States in-vitro diagnostics (IVD) market enormous potential for expansion over the period in analysis.
Opportunity - Rising adoption of automation in IVD labs
The increasing adoption of automated instruments and automation in laboratories is anticipated to present lucrative growth opportunities for United States In-Vitro Diagnostics (IVD) Market. Automated instruments provide several benefits, such as higher performance levels, enhanced productivity, data accuracy, and meeting safety protocols. As a result, many industry players are developing and launching automated instruments that offer higher efficiency and effectiveness in diagnostic tests. The increasing test volumes and shortage of skilled lab personnel are anticipated to boost automation in laboratories, thus, in turn, driving the growth of United States In-Vitro Diagnostics (IVD) Market.
Sample Request @ https://www.blueweaveconsulting.com/report/united-states-in-vitro-diagnostics-market/report-sample
0 notes
Text
In Vitro Diagnostics Market: Revolutionizing Healthcare with Advanced Diagnostics
The In Vitro Diagnostics (IVD) market plays a pivotal role in the healthcare industry, offering essential tools for disease diagnosis, treatment monitoring, and overall patient care. With advancements in diagnostic technology and the rising demand for personalized medicine, the IVD market is experiencing rapid growth. This article provides a detailed overview of the market trends, segmentation, key drivers, and leading companies in the IVD industry, offering valuable insights for decision-makers.
Market Overview
According to SkyQuest's In Vitro Diagnostics Market report, the global market is currently valued at USD 87.93 Billion in 2023, with a projected CAGR of 5.3% over the forecast period. The market is driven by the increasing prevalence of chronic diseases, advancements in diagnostic technologies, and the growing demand for early and precise disease detection.
Request Your Free Sample: - https://www.skyquestt.com/sample-request/in-vitro-diagnostics-market
Market Segmentation
By Product Type:
Reagents and Kits: Essential components used in diagnostic procedures across a range of diseases.
Instruments: Include advanced diagnostic tools like analyzers, molecular diagnostic machines, and point-of-care devices.
Software & Services: Diagnostic software for accurate test results and integrated solutions for laboratories.
By Technology:
Immunoassays: Widely used for infectious diseases and cancer diagnosis.
Molecular Diagnostics: Key in genetic testing and precision medicine applications.
Clinical Chemistry: Essential for routine testing and biomarker identification.
Microbiology: Used to identify pathogens and guide antibiotic therapies.
Hematology: Focuses on blood-related diagnostics such as complete blood count (CBC).
Others: Encompasses emerging technologies like proteomics and metabolomics.
By Application:
Infectious Diseases: Dominating the market due to the global rise in bacterial, viral, and fungal infections.
Oncology: Growing demand for early cancer diagnostics and targeted treatments.
Cardiology: Vital in diagnosing cardiovascular diseases and risk factors.
Diabetes: Includes blood glucose monitoring and HbA1c testing for diabetes management.
Other Applications: Includes diagnostics for autoimmune diseases, nephrology, and neurology.
By End-User:
Hospitals and Clinics: Major centers for diagnostic testing and patient care.
Diagnostic Laboratories: Specializing in high-volume testing across various disease areas.
Homecare Settings: Growing segment due to increasing demand for at-home diagnostic kits.
Academic and Research Institutes: Driving innovation in diagnostic tools and techniques.
Key Growth Drivers
Rising Prevalence of Chronic Diseases: Increasing cases of cancer, diabetes, and cardiovascular diseases fuel the demand for diagnostic tools.
Advancements in Technology: Development of rapid, accurate, and minimally invasive diagnostic methods is boosting the market.
Growing Demand for Personalized Medicine: The focus on tailored treatments and early diagnosis is driving the adoption of molecular diagnostics.
Expansion of Point-of-Care Testing (POCT): The shift towards decentralized testing is increasing the demand for portable and easy-to-use diagnostic devices.
Read More at: - https://www.skyquestt.com/report/in-vitro-diagnostics-market
Leading Companies in the Market
SkyQuest’s In Vitro Diagnostics Market report identifies key players that are shaping the market, including:
Roche Diagnostics
Abbott Laboratories
Siemens Healthineers
Danaher Corporation
Thermo Fisher Scientific
bioMérieux SA
Becton, Dickinson and Company
QIAGEN
Sysmex Corporation
Agilent Technologies
Take Action Now: Secure Your Report Today - https://www.skyquestt.com/buy-now/in-vitro-diagnostics-market
Challenges and Opportunities
The IVD market faces challenges such as stringent regulatory frameworks and high costs of diagnostic devices, especially in emerging markets. However, opportunities lie in the growing adoption of telemedicine, increased government funding for healthcare infrastructure, and technological advancements that enable faster and more precise diagnostic results.
Future Outlook
The In Vitro Diagnostics Market is expected to experience robust growth as healthcare providers increasingly rely on advanced diagnostics for effective patient care. Companies that invest in innovation and cater to the rising demand for point-of-care and home-based testing will have a competitive edge in this dynamic market.
As diagnostics play a critical role in healthcare, the In Vitro Diagnostics Market is poised for significant growth. Decision-makers should stay informed about emerging trends and technological advancements to leverage the full potential of this market. For more detailed insights and strategies, consult SkyQuest’s comprehensive In Vitro Diagnostics Market report.
0 notes
Text
Companion Diagnostics Market - Forecast(2024 - 2030)
Companion Diagnostic Market Overview:
The Harvard University, while addressing the risk associated with reactions of new drugs prescription, has stated some overwhelming facts. According to their findings, even properly prescribed drugs causes about 1.9 million hospitalizations a year and about 128,000 people die from drugs prescribed to them.[1] Such epidemic condition is being tailgated by the need of safe and effective and specific use of the drug. Owing to such demands, companion diagnostic drug market is poised for exponential growth. Companion diagnostics is an in-vitro diagnostic tool that assists physicians in optimizing treatment decisions for their patients and is crucial for myriad of cancer and other therapies. Riding on the back of economic burden of global healthcare and with abundant potential to restrict the liability, companion diagnostic market size is estimated to be $2,950 million as of 2018.
Inquiry Before Buying
Companion Diagnostic Market Outlook:
Companion diagnostic (CDx) is a diagnostic test used as an associate to a therapeutic drug to regulate its applicability to an individual person. It involves multiple monitoring methods including immunohistochemistry (IHC), polymerase chain Reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), and gene sequencing. The companion diagnostics uses technologies such as molecular biology technique, drug and diagnostic technology, and oncology therapy for the treatment of colorectal cancer, breast cancer, and other chronic diseases.
An acute analysis of the region-wise companion diagnostic market share concluded with reckoning North America as the most lucrative market for CDx. This region with cutting-edge healthcare technology in the United States and Canada generates 41% of the global companion diagnostic market demand for alarming need for cancer diagnosis and treatment. According to the American Cancer Society, prostate cancer is the most common cancer among males (19%), followed by lung (14%) and colorectal (9%) cancers and among females, breast (30%), lung (12%), and colorectal (8%) cancers are the most common. Increasing instances of cancer along with neurological disorders, infectious diseases, Hepatitis A is augmenting the North American companion diagnostic market.
Companion diagnostic market with abundant potential as an effective tool for personalized medicine has found a tremendous scope of application in pharmaceuticals, laboratories, research institutes and hospitals. Hospital as an end-user industry is the leading segment progressing with an application CAGR of 12.5% going through 2025. Hospitalized patients account for a total of 2.74 million serious adverse drug reactions. Each CDx test is specifically designed to be corresponding with an exact drug. Such tests can also save significant hospital expenditure by targeting specific patients with the most effective therapy.
Request Sample
Companion Diagnostic Market Trends and Growth Drivers:
· The necessity for personalized therapeutics for the cumulative geriatrics population and the increasing figure of diagnostics centers in both the developed and developing economies is predominant to determine profits in the global companion diagnostics market.
· FDA had issued "Guidance for Industry: In Vitro Companion Diagnostic Devices," to assist syndicates recognize the necessity for companion diagnostics at an initial stage in the drug development procedure and to strategize for co-development of the drug and companion diagnostic test.
On July 15, 2016, FDA introduced the draft regulation, "Principles for Co-development of an In Vitro Companion Diagnostic Device with a Therapeutic Product." This guidance text is envisioned to be a practical guide to support therapeutic product promoters and IVD sponsors in evolving a therapeutic product and an associated IVD companion diagnostic. The scientific progressions in the in-situ hybridization and automated silver-enhanced in-situ hybridization (SISH) for the monitoring of genes is trending in the global companion diagnostics market.
Schedule a Call
Companion Diagnostic Market Players Perspective:
Some of the key players influencing the global market are:- Abbott Laboratories, Agilent Technologies, biomerieux, Bio-Genex Laboratories, Danaher Corporation, GE Healthcare, Myriad Genetics, Inc., QIAGEN N.V., R-Biopharm AG, and Roche Diagnostics.
In April 2017, Abbott acquired Alere for a new price of about $5.3 billion. Alere is the global leader in point of care diagnostics focused on the areas of infectious disease, molecular, cardiometabolic and toxicology. The collective business will offer the biggest point of care menu of infectious disease, molecular, cardiometabolic and toxicology testing. Abbott's platforms will be expanded to comprise benchtop and rapid strip tests.
Buy Now
Companion Diagnostic Market Research Scope:
The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the companion diagnostic market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various diagnostics in companion diagnostic market, and their specific advantages.
#companion diagnostics market#companion diagnostics market size#companion diagnostics market share#companion diagnostics market forecast#companion diagnostics market report#drugs#chronic diseases#treatment#">
0 notes